View source for ABT-414

{{TreatmentInfo
|drug_name=ABT-414
|FDA_approval=No
|used_for=Targeting EGFR overexpressing glioblastoma cells
|clinical_trial_phase=Phase 1
|common_side_effects=Eye toxicities, especially blurred vision
|OS_with=Not reached at a median follow-up of 5.8 months
|PFS_with=6.1 months for all patients, 5.9 months for EGFR amplified patients
|usefulness_rating=2
|notes=ABT-414, an antibody-drug conjugate, selectively targets EGFR expressing tumor cells with minimal effects on healthy tissue. The phase 1 study highlighted challenges such as variable doses, study drug discontinuations due to toxicities, and small sample size, advising caution in evaluating efficacy parameters.
|treatment_category=Antibody-Drug Conjugates and other protein-drug conjugates
|links=
|toxicity_level=4
|toxicity_explanation=The drug ABT-414 is in phase 1 of its clinical trials. It demonstrates a tendency towards eye toxicities, especially causing blurred vision. This is an indication of potentially high toxicity. However, due to small sample size and other variables in the study, the evaluations should be taken with caution. It is advised to expect a higher level of toxicity until tested further in next clinical trial phases.
}}